Deal Share Platform

AVPN Global Conference 2023 | 20 - 22 June 2023

Days

Hrs

Mins

Secs

After decades of progress, malaria is on the rise again. Today, it kills 1,200 people a day, with close to 70% being children below 5. This amounts to a child dying every 2 minutes, from this entirely preventable disease. Unfortunately, 93% of the cases of malaria happen in sub-Saharan Africa, which includes some of the poorest countries in the world. Resources are short and global funding has proven woefully inadequate and any increased availability remains uncertain. In the last few years, the problem has been compounded by growing insecticide resistance observed in many countries. Apart from lives lost, malaria has a direct correlation to financial health: Malaria endemic countries have per capita income levels that are 70% lower than those of non-endemic countries.

Landcent has a unique two track approach to tackling malaria. Track 1 is to leapfrog current, proven technologies & design next generation versions that will disrupt the sector. We already have 2 out of 3 next-generation products in the final phase of testing. Track 2 is to develop new, safe, and entirely sustainable active ingredients (a.i.) that will stem the rise of vector resistance. The Gates Foundation is currently backing this project. Under Track 1 we have developed an Indoor Residual Spray (IRS) which has twice the residual effect of any IRS in the market. This is achieved through a unique micro-encapsulation innovation. Landcent also has a dual action long lasting insecticidal net (LLIN), which incorporates two highly effective insecticides. Under Track 2 we have studied a total of 57,407 natural compounds during the first period. These were then sifted down to 14 best candidates and are currently being evaluated for their potency against adult mosquitoes.